Transforming Clinical Trials with Digital Endpoints: Opportunities and Challenges

Transforming Clinical Trials with Digital Endpoints: Opportunities and Challenges

Digital endpoints have the potential to enhance traditional clinical data, deliver a real-world assessment of the patient’s experience, and reduce the cost/time of clinical trial programs.

So, where can digital endpoints deliver the most value?

What technologies and platforms are being deployed, and by whom?

How can the key challenges of identifying, validating and adopting novel digital endpoints be overcome?

Companies

AbbVie, Novartis, Teva, Lilly, GSK, AstraZeneca, Regeneron, Sanofi, UCB, Pfizer, Merck & Co., Jazz Pharmaceuticals, Genentech, Daiichi Sankyo, Takeda, Eisai, Bayer, Novo Nordisk, Boehringer Ingelheim, MedRhythms, Vanda, Withings, Abbott, Kyowa Kirin, Alkahest, Sarepta, ActiGraph, Johnson & Johnson, MC10, Medtronic, Addex Therapeutics, Vertex, Viatris, Idorsia Pharmaceuticals, Actelion, Ultragenyx, Bellerophon Therapeutics, Dexcom, Allurion Technologies, BioAge Labs, BioDelivery Sciences International, CereGate, Clario, Cionic, Clexio Biosciences, CuraSen Therapeutics, Diurnal Limited, EIP Pharma, Forest Laboratories, INmune Bio, Insulet Corporation, Khondrion, Marrek, Medicus Pharmaceuticals, Noema Pharma, Pharmacosmos, Praxis Precision Medicines, Sage Therapeutics, Signos, SoniVie, Tandem Diabetes Care, Zoll, Zucara Therapeutics